Chromothripsis

Bionano Genomics Reports Third Quarter 2022 Financial Results and Highlights Recent Business Progress

Retrieved on: 
Thursday, November 3, 2022

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • milestones
    Strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities at the end of Q3 2022
    SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September30, 2022.
  • We believe our Q3 2022 results, which include the highest quarterly revenues ever for Bionano, reflect continued gains in market development and commercial validation for OGM.
  • Total revenue for Q3 2022 was $7.2 million, up 55% from Q3 2021, and an 8% increase from Q2 2022.
  • Chris Stewart, chief financial officer of Bionano added, Q3 2022 was another outstanding quarter for Bionano.

Bionano Genomics Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Retrieved on: 
Thursday, August 25, 2022

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity.

Key Points: 
  • SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity.
  • The study compared the cytogenomic aberrations observed by genomic microarrays and chromosome banding analysis (CBA) to those observed using OGM.
  • The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.
  • Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability and utility of OGM to analyze chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity.

Bionano Genomics Hosts Day 2 of 2022 Symposium with New Research Demonstrating How OGM Detects Known and Novel Variants in Hematologic Malignancies

Retrieved on: 
Tuesday, January 11, 2022

Ten presentations from leading researchers across North America and Europe showcased the utility of OGM for hematologic malignancies at 2022 Symposium.

Key Points: 
  • Ten presentations from leading researchers across North America and Europe showcased the utility of OGM for hematologic malignancies at 2022 Symposium.
  • These researchers also shared examples of novel variants of potential clinical importance discovered with OGM that were undetected with other methods.
  • OGM revealed novel genetic aberrations in B-cell Chronic Lymphocytic Leukemia (B-CLL) and Acute Lymphoblastic Leukemias (ALL).
  • OGM detected more clinically relevant variants across a wide range of hematologic malignancies including acute myeloid leukemia (AML).

Bionano Genomics Announces Peer-Reviewed Publication from Johns Hopkins University Outlining a Stepwise Approach to the Adoption of Optical Genome Mapping for Cancer Analysis

Retrieved on: 
Monday, November 22, 2021

Sensitivity compared to CMA was 96% (22/23 CNVs detected) excluding copy neutral loss of heterozygosity calls.

Key Points: 
  • Sensitivity compared to CMA was 96% (22/23 CNVs detected) excluding copy neutral loss of heterozygosity calls.
  • OGM was also used in the study to provide high resolution analysis of subjects with complex karyotypes exhibiting chromothripsis.
  • Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.
  • The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.